Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Zakattack who wrote (3242)	6/8/1998 11:01:00 AM
From: AKAPAK	Respond to of 8798

NEWS OUT on ADOT !!! Press Release Today !!! Biomoda, Inc. in Discussions with Major German Pharmaceutical Affiliate, Discloses Biomoda Partner Advanced Optics Electronics Advanced Optics to Become Fully Reporting by July 15, 1998 ALBUQUERQUE, N.M.--(BUSINESS WIRE)--June 8, 1998--Advanced Optics Electronics,Inc. today disclosed that BIOMODA, INC. (in which Advanced Optics recently increased its ownership to 27%) has been contacted by BERLEX LABORATORIES on behalf of its parent company, SCHERING AG. Schering AG is a German-based pharmaceutical and medical technology company headquartered in Berlin. Schering AG, with over $3.8 Billion ($U.S.) in annual revenues and offices world-wide, is a recognized leader in biotechnology research and the use of contrast media in the diagnosis and treatment of a variety of diseases. Biomoda, Inc., a privately held emerging biotechnology company, holds an exclusive world-wide license for patented tests for the very early detection of lung cancer. Biomoda's sputum test, capable of detecting lung cancer at least six (6) years earlier than any currently available test, is uniquely integrated with an effective lung cancer treatment utilizing the same technology. Preliminary discussions have recently been held between representatives of Berlex Labs in Wayne, NJ and representatives of Biomoda, Inc. Berlex/Schering AG specializes in early diagnostics and therapy, two key areas addressed in Biomoda's cancer testing and treatment program. Schering AG invests approximately $700 Million annually in research and development. Of this amount, about 25% is used in collaboration with new and emerging technologies and companies. Berlex/Schering AG will make a determination on how best to proceed with Biomoda upon completion of Biomoda's testing of its early cancer test and treatment program. Biomoda is currently conducting these tests at a respected cytopathology lab in Arizona. Biomoda expects to complete its series of tests within twelve weeks. In other Company news, Advanced Optics Electronics expects to become a fully reporting company with the SEC as of July 15, 1998. A company spokesperson stated that, as a fully reporting company, ADOT positions itself to be followed by analysts and brokers in the investment community, both domestically and internationally. Advanced Optics Electronics, Inc. (OTC BB: ADOT - news) is a developer of patented electronic display technology, utilizing ADOT's proprietary SLM (Spatial Light Modulator) light valve. This industry-leading technology can be utilized in many diverse fields including the production of "television quality" advertising billboards, medical testing equipment, military displays, computer monitors and high definition video transmission. Advanced Optics Electronics actively seeks partnerships with companies in fields that could benefit from ADOT's patented technology. ADOT also owns a 27% interest in Biomoda, Inc., an emerging biotechnology company specializing in breakthrough cancer diagnostics and therapy. Advanced Optics Electronics, Inc. has retained first right of refusal to design, manufacture and distribute the necessary scanning testing devices for the lung cancer tests using Advanced Optics Electronics' proprietary display technology. This press release contains forward-looking statements with respect to the results of operations and business of the Company that involves risk and uncertainties. The Company's actual future results could materially differ from those discussed. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports to be filed with the Securities and Exchange Commission.